Humoral Response to SARS-CoV-2 MRNA Vaccine in Patients with Multiple Sclerosis Treated with Natalizumab

Overview

Journal Ther Adv Neurol Disord

Specialty Neurology

Date 2021 Aug 20

PMID 34413902

Citations 15

Authors

Rocco Capuano

Giovanna Donnarumma

Alvino Bisecco

Elena Grimaldi

Miriana Conte

Alessandro dAmbrosio

Federica Matrone

Mario Risi

Riccardo Maria Borgo

Manuela Altieri

Federica Giuliano

Nicola Coppola

Massimiliano Galdiero

Gioacchino Tedeschi

Antonio Gallo

Affiliations

Soon will be listed here.

Citing Articles

Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab.

Carvajal R, Zabalza A, Carbonell-Mirabent P, Martinez-Gomez X, Esperalba J, Pappolla A JAMA Netw Open. 2024; 7(4):e246345.

PMID: 38607624 PMC: 11015356. DOI: 10.1001/jamanetworkopen.2024.6345.

Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis.

OLeary S, Brugger H, Wallentine D, Sershon L, Goff E, Saldana-King T J Infus Nurs. 2023; 46(6):347-359.

PMID: 37920108 PMC: 10635346. DOI: 10.1097/NAN.0000000000000519.

Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in.

Pugliatti M, Hartung H, Oreja-Guevara C, Pozzilli C, Airas L, Alkhawajah M Front Immunol. 2022; 13:1045101.

PMID: 36325318 PMC: 9620960. DOI: 10.3389/fimmu.2022.1045101.

Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies.

Bellinvia A, Aprea M, Portaccio E, Pasto L, Razzolini L, Fonderico M Neurol Sci. 2022; 43(10):5783-5794.

PMID: 35918574 PMC: 9345744. DOI: 10.1007/s10072-022-06287-2.

Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis: a narrative review.

Capone F, Rossi M, Cruciani A, Motolese F, Pilato F, Di Lazzaro V Neural Regen Res. 2022; 18(2):284-288.

PMID: 35900404 PMC: 9396498. DOI: 10.4103/1673-5374.346539.

References

Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P . Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021; 14:17562864211012835. PMC: 8072850. DOI: 10.1177/17562864211012835. View

Riva A, Barcella V, Benatti S, Capobianco M, Capra R, Cinque P . Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. Mult Scler. 2020; 27(3):347-359. DOI: 10.1177/1352458520952310. View

Bonelli F, Blocki F, Bunnell T, Chu E, De La O A, Grenache D . Evaluation of the automated LIAISON SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. Clin Chem Lab Med. 2021; 59(8):1463-1467. DOI: 10.1515/cclm-2021-0023. View

Olberg H, Cox R, Nostbakken J, Aarseth J, Vedeler C, Myhr K . Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Mult Scler. 2014; 20(8):1074-80. DOI: 10.1177/1352458513513970. View

Vagberg M, Kumlin U, Svenningsson A . Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res. 2012; 34(7):730-3. DOI: 10.1179/1743132812Y.0000000059. View

Metze C, Winkelmann A, Loebermann M, Hecker M, Schweiger B, Reisinger E . Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies. CNS Neurosci Ther. 2018; 25(2):245-254. PMC: 6488907. DOI: 10.1111/cns.13034. View

Farez M, Correale J, Armstrong M, Rae-Grant A, Gloss D, Donley D . Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2019; 93(13):584-594. DOI: 10.1212/WNL.0000000000008157. View

Zheng C, Kar I, Chen C, Sau C, Woodson S, Serra A . Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs. 2020; 34(9):879-896. PMC: 7417850. DOI: 10.1007/s40263-020-00756-y. View

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

10.

Kristiansen P, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K . WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021; 397(10282):1347-1348. PMC: 7987302. DOI: 10.1016/S0140-6736(21)00527-4. View

11.

Kaufman M, Pardo G, Rossman H, Sweetser M, Forrestal F, Duda P . Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014; 341(1-2):22-7. DOI: 10.1016/j.jns.2014.03.035. View

12.

Kelly H, Sokola B, Abboud H . Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. J Neuroimmunol. 2021; 356:577599. PMC: 8095041. DOI: 10.1016/j.jneuroim.2021.577599. View

13.

Olberg H, Eide G, Cox R, Jul-Larsen A, Lartey S, Vedeler C . Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Eur J Neurol. 2017; 25(3):527-534. DOI: 10.1111/ene.13537. View